key: cord-0873608-old0xmcc authors: Zhao, Qianwen; Meng, Meng; Kumar, Rahul; Wu, Yinlian; Huang, Jiaofeng; Deng, Yunlei; Weng, Zhiyuan; Yang, Li title: Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis date: 2020-05-04 journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases DOI: 10.1016/j.ijid.2020.04.086 sha: 0537b59546c32791ba8cfd0ea35d6f809e427d6e doc_id: 873608 cord_uid: old0xmcc Abstract Objectives Coronavirus Disease 2019 (COVID-19) is a new respiratory and systemic disease which needs quick identification of potential critical patients. This meta-analysis aimed to explore the relationship between lymphocyte count and the severity of COVID-19. Methods Comprehensive systematic literature search was carried out to find studies published from December 2019 to 22 March 2020 from five Databases. The language of literatures included English and Chinese. Mean difference (MD) of lymphocyte count in COVID-19 patients with or without severe disease and odds ratio (OR) of lymphopenia for severe form of COVID-19 was evaluated with this meta-analysis. Results Overall 13 case-series with a total of 2282 cases were included in the study. The pooled analysis showed that lymphocyte count was significantly lower in severe COVID-19 patients (MD -0.31×109/L; 95%CI: -0.42 to -0.19×109/L). The presence of lymphopenia was associated with nearly threefold increased risk of severe COVID-19 (Random effects model, OR=2.99, 95% CI: 1.31-6.82). Conclusions Lymphopenia is a prominent part of severe COVID-19 and a lymphocyte count of less than 1.5×109/L may be useful in predicting the severity clinical outcomes. Microsoft Excel was used to analyze the clinical symptoms and the laboratory results. A meta-analysis was carried out using R software (version 3.6.3, available on 125 https://www.r-project.org). Heterogeneity among studies was tested using the Cochran 126 Chi-square test and I 2 , When I 2 < 50%, a fixed-effects model was used, while when 127 I 2 > 50%, a random-effects model was selected. If statistical heterogeneity was found 128 among the results, a further sensitivity analysis was conducted to determine the source 129 of heterogeneity. After the significant clinical heterogeneity was excluded, the 130 randomized effects model was used for meta-analysis. Funnel plot were used to detect 131 publication bias. P <0.05 was considered as statistical significance. Five studies reported the relationship between lymphopenia and the severity of 170 COVID- 19[11, 12, 15, 18, 19] . Lymphopenia was defined as a lymphocyte count of 171 less than 1.1×10 9 /L in four studies [11, 12, 16, 18] , and as less than 1.5×10 9 /L in 172 one [19] . The pooled OR as summarized in Figure 2C shows that the presence of After excluding this study, the I 2 of heterogeneity reduced to 48%, the OR of 178 lymphopenia was 2.17 (95% CI: 1.0126-4.6812). The funnel plot indicated no 179 publication bias inside this study ( Figure 2D ). In addition, another drawback of our study is that there is no data relating to From SARS to COVID-19: A previously unknown SARS-related 258 coronavirus (SARS-CoV-2) of pandemic potential infecting humans -Call for a One Health approach One health The continuing 2019-nCoV epidemic threat of novel 261 coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan, China Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) -United States The SARS-CoV-2 outbreak: What we know The impact of COPD and smoking history on the severity of Covid-19: A systemic review and meta-analysis Coronavirus disease 2019: What we know Functional exhaustion of antiviral lymphocytes in COVID-19 Molecular characterization of hepatitis C 273 virus in end-stage renal disease patients under hemodialysis Clinical features and treatment analysis of 79 Coronovirus infected 276 pneumonia Diagnostic Utility of Clinical Laboratory Data Determinations for 278 Patients with the Severe COVID-19 Analysis of factors associated with disease outcomes in hospitalized 280 patients with 2019 novel coronavirus disease Clinical and biochemical indexes from 2019-nCoV infected patients 282 linked to viral loads and lung injury Risk Factors Associated With Acute Respiratory Distress Syndrome 284 and Death in Patients With Coronavirus Disease Clinical Characteristics of 138 Hospitalized Patients With Clinical Features of 69 Cases with Coronavirus Disease 289 Clinical course and outcomes of critically ill patients with SARS-CoV-2 291 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet 292 Respiratory medicine Clinical course and risk factors for mortality of adult inpatients with Clinical Characteristics of Coronavirus Disease Retrospective study on the epidemiological 300 characteristics of 139 patients with novel coronavirus pneumonia on the effects of Severity Clinical features of patients infected with A major outbreak of severe acute respiratory syndrome in Hong Kong Clinical features and short-term outcomes of 144 307 patients with SARS in the greater Toronto area Hematological findings in SARS patients and possible mechanisms 309 (review) Effects of severe acute respiratory syndrome (SARS) coronavirus 311 infection on peripheral blood lymphocytes and their subsets Elevated exhaustion levels and reduced functional diversity 313 of T cells in peripheral blood may predict severe progression in COVID-19 patients Functional exhaustion of antiviral lymphocytes in COVID-19 COVID-19, cytokines and immunosuppression: what can 318 we learn from severe acute respiratory syndrome? Insight into 2019 novel coronavirus -An updated interim review and lessons from Lymphopenia predicts disease severity of COVID-19: a 322 descriptive and predictive study Acknowledgments: Not applicable.